Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: Prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs

Journal of Clinical Oncology

Volumn 30, Issue 33, 2012, Pages 4098-4103

  Emanuel, Robyn M ^a   Dueck, Amylou C ^a   Geyer, Holly L ^a   Kiladjian, Jean Jacques ^b   Slot, Stefanie ⁱ   Zweegman, Sonja ⁱ   Te Boekhorst, Peter A W ^j   Commandeur, Suzan ^k   Schouten, Harry C ^l   Sackmann, Federico ^m   Fuentes, Ana Kerguelen ⁿ   Hernández Maraver, Dolores ⁿ   Pahl, Heike L ^q   Griesshammer, Martin ^r   Stegelmann, Frank ^s   Doehner, Konstanze ^s   Lehmann, Thomas ^u   Bonatz, Karin ^t   Reiter, Andreas ^t   Boyer, Francoise ^c   Etienne, Gabriel ^d   Ianotto, Jean Christophe ^e   Ranta, Dana ^f   Roy, Lydia ^g   Cahn, Jean Yves ^h   Harrison, Claire N ^v   Radia, Deepti ^v   Muxi, Pablo ^w   Maldonado, Norman ^x   Besses, Carlos ^o   Cervantes, Francisco ^p   Johansson, Peter L ^y   Barbui, Tiziano ^ab   Barosi, Giovanni ^ac   Vannucchi, Alessandro M ^ad   Passamonti, Francesco ^ac   Andreasson, Bjorn ^y   Ferarri, Maria L ^ab   Rambaldi, Alessandro ^ab   Samuelsson, Jan ^z   Birgegard, Gunnar ^aa   Tefferi, Ayalew ^ae   Mesa, Ruben A ^a   more..

^a MAYO CLINIC   (United States)

^b SAINT LOUIS HOSPITAL   (France)

^c ANGERS UNIVERSITY HOSPITAL   (France)

^d INSTITUT BERGONIÉ   (France)

^e BREST UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY HOSPITAL OF NANCY   (France)

^g POITIERS UNIVERSITY HOSPITAL   (France)

^h GRENOBLE UNIVERSITY HOSPITAL   (France)

ⁱ VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^j ERASMUS MEDICAL CENTER   (Netherlands)

^k LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^l MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^m Fundacion para Combatir La Leucemia   (Argentina)

ⁿ HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^o HOSPITAL DEL MAR   (Spain)

^p UNIVERSITY OF BARCELONA   (Spain)

^q UNIVERSITY OF FREIBURG   (Germany)

^r KLINIKUM MINDEN   (Germany)

^s UNIVERSITY HOSPITAL ULM   (Germany)

^t UNIVERSITY OF HEIDELBERG   (Germany)

^u UNIVERSITY HOSPITAL BASEL   (Switzerland)

^v GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^w British Hospital Montevideo   (Uruguay)

^x UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^y NU Hospital Organization   (Sweden)

^z STOCKHOLM SÖDER HOSPITAL   (Sweden)

^aa UPPSALA UNIVERSITY   (Sweden)

^ab OSPEDALI RIUNITI   (Italy)

^ac UNIVERSITY OF PAVIA   (Italy)

^ad UNIVERSITY OF FLORENCE   (Italy)

^ae MAYO CLINIC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL DISCOMFORT; ADULT; AGED; ARTICLE; BONE PAIN; CLINICAL FEATURE; CONTROLLED STUDY; CRONBACH ALPHA COEFFICIENT; FATIGUE; FEMALE; FEVER; HUMAN; IMMOBILIZATION; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; MYELOPROLIFERATIVE NEOPLASM SYMPTOM ASSESSMENT FORM TOTAL SYMPTOM SCORE; NIGHT SWEAT; PATIENT ASSESSMENT; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; SATIETY; SCORING SYSTEM; THROMBOCYTHEMIA; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE; YOUNG ADULT;

EID: 84869381382     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.3863     Document Type: Article

References (9)

1. Pardanani A, Gotlib JR, Jamieson C, et al: Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 29:789-796, 2011
2. Mesa RA, Kantarjian H, Tefferi A, et al: Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: Performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer 117:4869-4877, 2011
3. Mesa RA, Niblack J, Wadleigh M, et al: The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): An international Internetbased survey of 1179 MPD patients. Cancer 109:68-76, 2007
4. Mesa RA, Schwager S, Radia D, et al: The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res 33:1199-1203, 2009
5. Scherber R, Dueck AC, Johansson P, et al: The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International prospective validation and reliability trial in 402 patients. Blood 118:401-408, 2011
6. Mendoza TR, Wang XS, Cleeland CS, et al: The rapid assessment of fatigue severity in cancer patients: Use of the Brief Fatigue Inventory. Cancer 85:1186-1196, 1999
7. Wild D, Grove A, Martin M, et al: Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: Report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health 8:94-104, 2005
8. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
9. Verstovsek S, Mesa RA, Gotlib J, et al: A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366:799-807, 2012